Liraglutide starts at 0.6 mg daily, increasing by 0.6 mg each week over five weeks until reaching the maintenance dose of 3 mg
Anything cloudy, brown, layered, or with visible particles is not
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
The fact that the lean body mass decreased from four to eight weeks in the Setria and placebo groups suggests bad experimental design (the researchers hypothesized "eating less" and "over-reaching") -- these variables should be better accounted for in a proper study
70 percent isopropyl alcohol prep pads, one per septum entry and one per injection site
In SURMOUNT-1, the most common treatment-emergent adverse events were gastrointestinal: nausea (24.6-33.3% across doses vs 9.5% placebo), diarrhea (18.7-21.2%), vomiting (5.7-12.2%), and constipation (5.8-11.5%)